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Abstract
Background:  Previous reports suggest an as yet unidentifiable subset of patients with
plasmacytoma will progress to myeloma. The current study sought to establish the risk of
developing myeloma and determine the prognostic factors affecting the progression of disease.
Methods: Patients with plasmacytoma diagnosed between 1973 and 2005 were identified in the
SEER database(1164 patients). Patient demographics and clinical characteristics, treatment(s), cause
of death, and survival were extracted. Kaplan-Meier, log-rank, and Cox regression were used to
analyze prognostic factors.
Results: The five year survival among patients initially diagnosed with plasmacytoma that later
progressed to multiple myeloma and those initially diagnosed with multiple myeloma were almost
identical (25% and 23%; respectively). Five year survival for patients with plasmacytoma that did not
progress to multiple myeloma was significantly better (72%). Age > 60 years was the only factor
that correlated with progression of disease (p = 0.027).
Discussion: Plasmacytoma consists of two cohorts of patients with different overall survival; those
patients that do not progress to systemic disease and those that develop myeloma. Age > 60 years
is associated with disease progression. Identifying patients with systemic disease early in the
treatment will permit aggressive and novel treatment strategies to be implemented.
Introduction
Plasmacytoma results from clonal proliferation of plasma
cells that are identical to plasma cells of myeloma on both
the cyotologic and immunophenotypic levels. Plasmacy-
toma can be subclassified as osseous disease or extraos-
seous tumor [1-7]. The clinical presentation of these
diseases represent different groups of patients in terms of
location, tumor progression, and overall survival rate [8];
however, they share many of the biologic features of other
plasma cell disorders [1,9]. Skeletal plasmacytoma is char-
acterized clinically by a radiolytic lesion involving any
part of the skeleton, a clonal plasma cell infiltrate and an
absence of disseminated bone marrow involvement.
Local radiotherapy and alternatively surgery are treatment
options yielding adequate local control [7,10]. Despite
local treatment efforts, 50-60% of patients with plasmacy-
toma progresses to myeloma [2,11,12]. It has been
reported that skeletal plasmacytoma is known to progress
more frequently to multiple myeloma than extraskeletal
disease [2,11,13]. Most of the basis for the natural history
of plasmacytoma is derived from reports emanating from
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single institutions. Knobel et al and Kilciksiz et al reported
multi-center experiences but the small number of patients
limited the statistical power of these studies[10,14].
Recently Dores et al reported incidence and survival for
patients with plasmacytoma, extraskeletal disease and
myeloma from the SEER database [15]. In this study there
was no analysis of prognostic factors associated with nei-
ther progression of cases initially diagnosed as plasmacy-
toma into myeloma nor an assessment of local disease
control.
The current manuscript attempts to ascertain the impact
of local treatment on disease progression in patients with
skeletal plasmacytoma. Specifically, the study sought to
establish the incidence of development of myeloma and
the treatment outcomes of patients initially diagnosed
with plasmacytoma. Furthermore, the study seeks to com-
pare clinical parameters in cases of plasmacytoma not
progressing to systemic disease with those developing into
myeloma to identify prognostic factors. In order to answer
these questions, the SEER Database was utilized as a
source of patient data. Previously the population based
SEER database has been used to describe the outcomes for
breast, colorectal, prostate, lung, ovarian, sarcomas and
neuroectodermal cancers and has been validated as to the
accuracy [16-21]. The current study investigates the
impact of local treatment on skeletal plasmacytoma and
its progression to myeloma and demonstrates that a
younger patient population has localized disease which
does not progress to systemic disease.
Methods
The Surveillance, Epidemiology, and End-Results (SEER)
Program of the National Cancer Institute (NCI) was estab-
lished as a direct result of the National Cancer Act 1971.
Currently SEER collects data from 17 population based
registries covering approximately 26% of the US popula-
tion. It is the only comprehensive source of population
based data in the U.S. that includes the stage of cancer at
the time of diagnosis and follow-up of all patients for sur-
vival data. In addition, each registry collects data on
patient demographics, primary tumor site and morphol-
ogy, and first course of treatment (occurring within 4
months of diagnosis) [22-34]. The SEER program is cur-
rently regarded as the standard of quality among cancer
registries around the world with case completeness of
98% [35].
The SEER database was used to identify all cases of skeletal
plasmacytoma diagnosed from 1973-2005 using Interna-
tional Classification of Disease for Oncology, 3rd Edition
(ICD-O-3) [36]. We used primary site of lesion to specifi-
cally select for cases involving bone. A total of 1164
patients were identified and information regarding
patient demographics, clinical characteristics, treatment
related characteristics were extracted (if provided within 4
months of diagnosis), and survival time (months) until
death or loss to follow-up. Percentages were based on
available data for each individual variable. Patients with
missing data were excluded from each respective univari-
ate and multivariate analysis.
Patients' age was converted to a categorical variable (0-29,
30-59, >60) for the purpose of analysis. The appendicular
skeleton included long and short bones of limbs and asso-
ciated joints, and the scapula. Axial skeleton included ver-
tebra, ribs, sternum, clavicle and associated joints, bones
of skull, face and associated joints, mandible, and pelvic
bones. Staging categories of local, regional, and distant
were described in SEER according to AJCC staging system
[37]. Since, skeletal plasmacytoma by definition is a local-
ized disease process we excluded the cases (5.6% of total)
designated as 'distant'. Year of diagnosis was categorized
in four categorical variables: 1973-1975, 1976-1985,
1986-1995, and 1996-2005. Results reported herein are in
compliance with the Health Insurance Portability and
Accountability Act of 1996.
Incidence rates were age adjusted and normalized using
the 2000 US Standard population [38]. Statistical analysis
was performed using SPSS version 17.0 (SPSPSS Inc., Chi-
cago, IL). Chi-square test was used to make correlations
between categorical variables. Overall and disease-specific
survival from the time of initial diagnosis to the date of
last contact (or the date of death) was calculated using the
Kaplan-Meier method. The effects of demographic, clini-
cal, pathological, and treatment variables were tested
using the log-rank test for categorical values. A multivari-
ate analysis was carried out for determination of inde-
pendent prognostic factors using the Cox proportional
hazards model. All prognostic factors found to be signifi-
cant in the univariate analysis, namely gender, stage, pri-
mary site, size, and surgical therapy were included in a
multivariate analysis.
Results
A total of 1164 cases of plasmacytoma are included in the
SEER Data-base from 1973-2005. Nearly three quarter of
the cases (74.7%) were diagnosed during the most recent
decade, 1996-2005 reflecting the geographic expansion of
the data collection effort during these years. The demo-
graphic and clinical characteristics of the entire patient
cohort are summarized in Table 1. Most patients were
older than 60 years at diagnosis (63.7% of the cases).
Males comprised 61.9% of patients; race was predomi-
nantly Caucasian (84.1%) and ethnicity predominantly
non-Hispanic (89.7%), respectively. Among all the cases
identified, 5.2% of the tumors were designated as 'distant'
at the time of diagnosis and thus were excluded from fur-
ther analysis. Staging information was available for 51.4%Journal of Hematology & Oncology 2009, 2:41 http://www.jhoonline.org/content/2/1/41
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of the cases that were subjected to analysis. Surgical resec-
tion alone was performed in 34.6% of patients, solely
radiation therapy administered in 53.9%, and combined
surgery and radiation in 0.9%. Approximately 10.5% of
patients received no therapy for local disease control
(dns).
The overall incidence for plasmacytoma was 0.3462/
100,000 in 2005; similar to what has been reported by
Dores et al [15]. Afro-American to Caucasian Incidence
Rates Ratio to develop plasmacytoma was found to be
approximately 1.30 (dns). Five and ten year overall sur-
vival for patients with skeletal plasmacytoma is summa-
rized in Table 2. Kaplan-Meier prediction of survival of
patients with plasmacytoma is affected by race with "races
other than Caucasians" and Afro-Americans faring signif-
icantly better than Caucasians (p < 0.001). Since other
races made up only 4.2% of the entire patient cohort, thus
this result should be interpreted with caution. There was
no significant difference in outcome between Caucasians
and Afro-Americans.
Patients diagnosed at age < 60 years (Figure 1) had a sig-
nificantly better 5 year survival (90% for patients aged 0-
29 years & 80% for patients 30-59 years) when compared
to patients diagnosed at age >60 years (5 year survival
45%) (p < 0.001). Patients with skeletal plasmacytoma
had an overall survival of 57% at 5 years and 37% at 10
years. Females have a significantly lower 5 and 10 year
survival than males (5 year survival 54% v/s 59% for
males (p-value = 0.008). Patients with a solitary lesion
carried significantly better prognosis with a 5 year survival
of 59% as compared to 36% for patients with more than
2 lesions (p = 0.032). There was no significant difference
in survival between patients with a single or two lesions
(p-value = 0.28). There was no significant difference in 5
year survival outcome for axial lesions (58%) as com-
pared to appendicular lesions (52%) (p = 0.24).
Patients undergoing surgery fared no better than patients
without resection (5 year survival 59% and 56% respec-
tively, p = 0.29). In contrast, administration of radiation
therapy was associated with an improvement in survival
(5 year survival of 60% among patients with radiation
therapy as compared to 46% without any radiation ther-
apy, p < 0.001). Further analysis revealed that use of any
local disease control modality, either surgery or radiation
therapy was associated with better outcomes as compared
to the absence of any local disease control (p < 0.001; Fig-
ure 2). Surgery and radiation were found to be equally
effective in local disease control. Use of both modalities
was not associated with any significant survival advan-
tage. No significant improvement in survival could be
observed over time when stratified by decade for the past
two decades (p = 0.19).
Table 3 illustrates a step-wise multivariate analysis
employing the Cox proportional hazard model to ascer-
tain the independent significant variables for the entire
cohort. The parameters age > 60 years (p < 0.001), race
other than Caucasians and Afro-Americans (p < 0.05),
and absence of radiation therapy (p < 0.001) were all
independent predictors of lower overall survival.
In order to compare the plasmacytoma as a localized dis-
ease with cases progressing to myeloma, the survival and
cause of death information were extracted regarding all
the cases of multiple myeloma from 1973-2005 (54,244
cases). We found that there was no significant difference
in 5 year survival among patients initially diagnosed with
multiple myeloma and those initially labeled as plasma-
cytoma who subsequently later progressed to multiple
myeloma (5 year survival of 25% and 23% respectively).
Table 1: Demographic and clinical characteristics of the entire 
patient cohort
n Valid % of total
Total Patients 1,164 100
Age
0-29 13 1.1
30-59 410 35.2
>60 741 63.7
Gender
Male 720 61.9
Female 444 38.1
Race
White 973 84.1
Black 135 11.7
Other 49 4.2
Ethnicity
Hispanic 119 10.3
Non-Hispanic 1,035 89.7
Stage
Local 598 100
Lesion
Single 960 82.5
Two 180 15.5
>Two 24 2.1
Location
Bone NOS 15 1.3
Appendicular 187 16.1
Axial 962 82.6
Surgery
Yes 404 34.9
No 752 65.1
Radiation
Yes 927 80.9
No 219 19.1
Year of Diagnosis
1973-1975 2 0.2
1976-1985 27 2.3
1986-1995 265 22.8
1996-2005 870 74.7Journal of Hematology & Oncology 2009, 2:41 http://www.jhoonline.org/content/2/1/41
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In contrast, 5 year survival for patients with plasmacy-
toma who did not progress to multiple myeloma was sig-
nificantly better with (p < 0.001 5 year survival = 72%),
Figure 3. Some of the more frequent causes of death in
patients with plasmacytoma not progressing to myeloma
included Diseases of Heart (4.5%) and Cerebrovascular
Diseases (1.0%) as would be expected for patients in this
age group.
Analysis of statistically significant factors on multivariate
analysis did not reveal any prognostic factors significantly
associated with progression of plasmacytoma into a sys-
temic disease other than age (Table 4). Association
between Age >60 years and development of myeloma
approached significance (p = 0.027).
In order to assess the potential ascertainment bias: the
potential bias of falsely diagnosing patients with mye-
loma as plasmacytoma patients, a cross-tabulation was
performed between cause of death and different treatment
groups. Our analysis reveals 27 of 60 patients with no
attempt at local control, died of myeloma. This ratio of
progression to myeloma was similar in other treatment
groups (dns) with chi-square not revealing any statistical
significance.
Discussion
The current study is the first to demonstrate the impact of
local treatment on skeletal plasmacytoma using a popula-
tion based registry. It further demonstrates the differences
in treatment related outcomes among patients diagnosed
Table 2: Disease-specific survival according to demographic and clinical characteristics (proportion surviving)
5-Year Survival 10-Year Survival p-value
Overall 0.57 0.37 n/a
Age
0-29 0.9 0.9
30-59 0.8 0.63
>60 0.45 0.23 <0.001*
Gender
Male 0.59 0.4 0.008
Female 0.54 0.32
Race
White 0.56 0.36
Black 0.56 0.37
Other 0.76 0.64 0.001**
Ethnicity
Hispanic 0.65 0.47 0.152
Non-Hispanic 0.56 0.36
Stage
Local 0.54 0.38 n/a
Lesion
Single 0.59 0.39 0.032***
Two 0.53 0.36
> Two 0.36 0.15
Location
Bone NOS n/a n/a
Appendicular 0.52 0.33
Axial 0.58 0.39 0.240****
Surgery
Yes 0.59 0.4 0.286
No 0.56 0.36
Radiation
Yes 0.6 0.39 <0.001
No 0.46 0.31
Year of Diagnosis
1973-1975 1 1
1976-1985 0.63 0.44
1986-1995 0.52 0.32 0.072*****
1996-2005 0.59 0.42
P value shown for Log rank test between variables; *p < 0.001 for age 0-29 vs. >60 and. 30-59 vs. >60, 30-59 vs. 0-29: p = 0.158; **p = 0.001 for 
White vs. Other only, White vs. Black: p = 0.932, and Black vs. Other: p = 0.006; ***p = 0.032 for Single vs. >Two only, Single vs. Two: p = 0.275, 
Two vs. > Two only: p = 0.182; ****p = 0.240 for Appendicular vs. Axial only, Bone NOS vs. Appendicular: p < 0.001, Bone NOS vs. Axial: p < 
0.001; *****p < 0.072 for 1973-1975 vs. 1986-1995 only, 1973-1975 vs. 1976-1985: p = 0.125, 1973-1975 vs. 1996-2005: p = 0.109, 1976-1985 vs. 
1986-1995: p = 0.486, 1976-1985 vs. 1996-2005: p = 0.365, 1986-1995 vs. 1996-2005: p = 0.194.Journal of Hematology & Oncology 2009, 2:41 http://www.jhoonline.org/content/2/1/41
Page 5 of 8
(page number not for citation purposes)
with plasmacytoma not progressing to myeloma, those
that progressed to myeloma. Epidemiological studies
comparing SEER areas to non-SEER areas in the U.S. con-
clude that their age and sex distributions are comparable
except that SEER areas tended to be more affluent and
more urban than non-SEER areas [34]. When compared to
NPCR and USCS, incidence rates for all sites combined
were lower in SEER. But for category of interest: 'Bones
and Joints', the differences were small: 0.6 in SEER versus
0.8 per 100,000 in NPCR among Black males was the larg-
est reported difference [34]. Despite adequate local con-
trol with radiotherapy and/or surgery, cause of death in
59% of the patients initially diagnosed with plasmacy-
toma was progression to myeloma. Similarly, Soutar et al.
reported >75% progression to multiple myeloma for skel-
etal plasmacytoma [12]. In the current study it cannot be
determined that what is the absolute rate of progression to
multiple myeloma among patients diagnosed with plas-
macytoma, since some of the patients died of other causes
and hence are censored. Despite these limitations, we can
confidently say that rate of progression to Multiple Mye-
loma among cases of plasmacytoma is at least 59% and
may be slightly greater than this number.
Also, the 5 year survival for patients diagnosed with mul-
tiple myeloma and those diagnosed as plasmacytoma ini-
tially but who subsequently developed myeloma later on,
were almost identical (Figure 3). This may suggest an
underlying misdiagnosis for cases of myeloma as plasma-
cytoma. In order to overcome this problem, the use of
MRI in initial staging of plasma cell neoplasm has been
advocated by some authors [39] while others have
reported conflicting evidence [14]. We tried to address
this issue by determining any significant association of the
independent predictors of overall survival among patients
with plasmacytoma and subsequent development of mul-
tiple myeloma. None of the factors considered revealed
any significant association with development of mye-
loma, other than age. Age > 60 years was significant with
a p = 0.027 (Table 4). Conflicting evidence for age as a
predictor of progression to myeloma has been reported in
literature, with some studies supporting this observation
[3,40-42] while others have found no association [43-45].
Kilciksiz et al. identified age as an independent prognostic
factor for progression to myeloma [10].
Another controversy highlighted in literature involves the
fate of patients with plasmacytoma in regards to disease
progression. While some have demonstrated a significant
portion of patients free of disease after 5 and 10 years, oth-
ers believe in the inevitability of progression for all
patients [41,43,46,47]. The current study clearly demon-
strates that there is a cohort of plasmacytoma patients that
do not progress to myeloma demonstrate as high as 72%
5-year survival rate (Figure 3).
Overall Survival stratified by Age Figure 1
Overall Survival stratified by Age.
Overall Survival stratified by Local Treatment Figure 2
Overall Survival stratified by Local Treatment.Journal of Hematology & Oncology 2009, 2:41 http://www.jhoonline.org/content/2/1/41
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Surgery alone has been proposed as the best treatment
option for extramedullary plasmacytomas [48], but con-
flicting evidence has also been provided in the literature
[14]. Uni- and multivariate analysis in the current study
revealed no survival advantage associated with surgery
alone for skeletal plasmacytoma (Table 2). This result
reflects a selection bias: relatively smaller number of
patients underwent surgical resection as a local treatment
option. Radiotherapy was employed for a majority of
cases. Further analysis, after stratification based on local
treatment option clearly demonstrates that use of either
option, i.e. surgical therapy or radiotherapy is associated
with an improvement in survival in skeletal disease. Nei-
ther of the treatment options showed a survival benefit
over the other nor similarly employment of both modali-
ties of local control did not further improve survival.
Limitations of the current study include lack of any infor-
mation on specific chemotherapy regimens or any other
adjuvant therapy in the SEER Database. Thus we are una-
ble to comment directly on survival benefit conferred
upon by the use of chemotherapy or efficacy of a particu-
lar regimen in a particular subset of patients. Similarly, no
information regarding any medical history, radiological
studies or serological work up is provided in the database
limiting our analysis on diagnostic accuracy of MRI, and
prognostic significance of absence of myeloma protein,
anemia, hypercalcemia, renal insufficiency and stability of
M-protein. Accuracy of staging information can be a
potential pitfall in all studies based on database. Another
Table 3: Cox proportional hazards model for risk of death from Ewing's Sarcoma
n Hazard ratio 95% CI p-value
Age
0-29 13 0.075 0.011-0.537 0.01
30-59 401 0.277 0.220-0.349 <0.001
>60 726 Reference Group
Gender
Male 710 0.918 0.764-1.103 0.362
Female 430 Reference Group
Race
White 957 1.893 1.037-3.455 0.038
Black 134 2.080 1.086-3.985 0.027
Other 49 Reference Group
Lesions
Single 939 0.851 0.523-1.387 0.518
Two 177 0.85 0.504-1.434 0.542
> Two 24 Reference Group
Radiation
Yes 925 0.647 0.521-0.804 <0.001
No 215 Reference Group
CI: Confidence Interval
Overall Survival stratified by Disease Progression Figure 3
Overall Survival stratified by Disease Progression.
Table 4: Prognostic Factors Associated with Progression
Myeloma Other Causes Chi-Square
Age
0-29 years 0 1 0.027
30-59 years 71 31
60+ years 245 188
Race
White 277 191 0.457
Black 34 22
Others 5 7Journal of Hematology & Oncology 2009, 2:41 http://www.jhoonline.org/content/2/1/41
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issue associated with the reported data in SEER is the
potential bias of falsely labeling myeloma patients as plas-
macytoma patients. The results of bone marrow aspirate
are not reported in SEER, and in clinical practice treatment
decisions are usually made based on this parameter. This
raises the suspicion of marrow involvement >30% among
those not receiving the local therapy. Our analysis reveals
no correlation between any treatment groups and 'cause
of death'. We also attempted to address the controversy
regarding progression to myeloma. In clinical practice, the
evaluation regarding progression to myeloma is carried
out after a specified time interval. SEER does not report
the time for evaluation regarding progression; we assessed
the outcome using 'cause of death' information. The time
to progression cannot be assessed.
Conclusion
Despite the above mentioned limitations such as retro-
spective nature of data, lack of information about chemo-
therapy or serological or radiological investigations; the
current study addresses some of the controversies in dis-
ease progression and impact of local treatment for plas-
macytoma using a large populations based well validated
national database. The current study also reiterates the
need of better understanding of the disease process of
plasma cell neoplasm and the inclusion of molecular
markers in the database.
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